Insmed Inc. sell klostergang
Start price
05.09.17
/
50%
€23.52
Target price
29.12.17
€16.24
Performance (%)
20.60%
End price
29.12.17
€28.36
Summary
This prediction ended on 29.12.17 with a price of €28.36. The prediction closed with a disappointing performance of 20.60%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Insmed Inc. | 27.653% | 27.653% | 8.733% | 443.663% |
| iShares Core DAX® | 0,44 % | 5,64 % | 7,81 % | 63,64 % |
| iShares Nasdaq 100 | 1,06 % | 0,28 % | 27,24 % | 88,12 % |
| iShares Nikkei 225® | 1,77 % | 0,41 % | 49,27 % | 83,53 % |
| iShares S&P 500 | 0,37 % | 1,92 % | 22,34 % | 68,75 % |
Comments by klostergang for this prediction
In the thread Insmed Inc. diskutieren
klostergang stimmt der Sell-Einschätzung von kyron7htx zu
The open-label design of the Phase 3 trial will likely have a negative impact on secondary outcomes and may hinder the robustness of Insmed's NDA.
(Vom Mitglied beendet)